Carcinotech
Develops 3D bioprinted living tumor models from patient-derived cells to accelerate oncology drug discovery and personalized medicine.
- CEO / Founder
- Ishani Malhotra
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- £7.3M
- Latest Round
- Pre-Series A
- Key Investors
- Eos Advisory, Tricapital, Gabriel Investments, Scottish Enterprise, SIS Ventures, Alba Equity, Maven Capital Partners, Old College Capital, Investing Women Angels
Technology & Products
Key Products
Carcinotech develops 3D-bioprinted tumor models and utilizes Carcino3D technology for preclinical oncology services, accelerating cancer research and precision medicine.
Technological Advantage
Claimed to be the only company using 3D-printed living tumors for drug testing; technology validated through partnerships with Cancer Research UK and Cellink.
Differentiation
Value Proposition
Replicates the complex tumor microenvironment using patient-derived cells to provide more accurate drug testing results than 2D or homogenous 3D models, accelerating the drug development timeline.
How They Differentiate
Utilizes living 3D-printed tumors with patient-specific immune cells and mutational data, whereas competitors primarily use 2D models or homogenous 3D models.
Market & Competition
Target Customers
Pharmaceutical companies, Contract Research Organizations (CROs), surgeons, pathologists, and clinicians.
Industry Verticals
Oncology; Pharmaceuticals; Personalized Medicine; Clinical Pathology
Competitors
Cellink
Growth & Milestones
Growth Metrics
Secured £4.2m funding for US expansion; developed tumor models for 5 cancer types (brain, lung, breast, colorectal, ovarian).
Major Milestones
Founded in 2018 based on University of Edinburgh research; Secured £4.2m funding for US expansion; Established partnerships with Cellink and Cancer Research UK; Developed characterized tumor models for five cancer types
Notable Customers
Cancer Research UK; CELLINK; University of Edinburgh (Usher Institute)